bioAffinity Technologies (NASDAQ:BIAF) Coverage Initiated by Analysts at Maxim Group

Maxim Group started coverage on shares of bioAffinity Technologies (NASDAQ:BIAF) in a research note released on Tuesday, MarketBeat reports. The firm issued a buy rating and a $6.00 price target on the stock.

bioAffinity Technologies Price Performance

Shares of BIAF stock opened at $2.71 on Tuesday. The firm’s 50 day moving average price is $2.31 and its two-hundred day moving average price is $2.10. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.21 and a current ratio of 2.22. bioAffinity Technologies has a 52-week low of $0.95 and a 52-week high of $3.62. The stock has a market cap of $31.60 million, a PE ratio of -2.91 and a beta of 2.99.

bioAffinity Technologies (NASDAQ:BIAF) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter. The company had revenue of $2.41 million during the quarter. bioAffinity Technologies had a negative return on equity of 134.34% and a negative net margin of 171.43%.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.